H3 Drug Discovery Partnership

The University of Cape Town's Drug Discovery and Development Centre (H3-D) is to collaborate with global pharmaceutical firm Novartis to narrow the gap between science and clinical research in order to develop medicines to treat patients in Africa.

H3 Drug Discovery Partnership

H3-D is the first drug discovery centre in Africa, with an initial research focus on TB and malaria, two top medical needs on the continent. Last year, the first compound developed by H3-D was endorsed by the Medicines for Malaria Venture as a pre-clinical anti-malarial candidate.

Through this partnership, Novartis supports the Centre’s efforts to bridge the gap between basic and clinical studies, training a new generation of African scientists with key skills required for drug discovery and development – integrating medicinal chemistry, disease biology, and pharmacology.

For example, through this collaboration Novartis helped H3-D to develop an FDA-­level clinical site to conduct Phase I clinical studies of new medicines discovered by the Centre in Cape Town, South Africa. Additionally, Novartis supports H3-­D in the design of medicines against tuberculosis (TB), and conduct joint programs on malaria research with the Singapore-­based Novartis Institute for Tropical Diseases (NITD).


  • Novartis AG

    Goods Supplier
    Switzerland | Staff size: 10,000+

    Novartis AG, was incorporated on 1996, provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of...

  • Medicines for Malaria Venture (MMV)

    Foundation, Institute
    United States | Staff size: Unknown

    MMV, a not-for-profit public-private partnership, was established as a foundation in Switzerland. It was created to discover, develop and deliver new, effective and affordable drugs for malaria...

  • African Institute of Biomedical Science and Technology (AiBST)

    Zimbabwe | Staff size: Unknown

    AiBST is a hybrid institute with elements of tertiary academic institutions and biomedical R&D companies to enable it to operate in an environment which still requires capacity and...

  • Bio Ventures for Global Health (BVGH)

    Development Consulting
    United States | Staff size: 6-25

    BIO Ventures for Global Health (BVGH) is a results-oriented nonprofit organization dedicated to solving global health issues by forming connections between people, resources, and...

More Resources

Key Information

LocationSouth Africa, Southern Africa
  • Start Date 2012